Wilmington PharmaTech, a U.S.-based specialty contract research, development, and manufacturing organization known for its work in custom small molecule API development, has announced a majority investment from Curewell Capital. The Los Angeles-based private equity firm is focused on supporting and scaling healthcare companies across the industry. Hui-Yin “Harry” Li, Ph.D., who founded WPT and currently serves as CEO, will remain a key stakeholder in the company and will continue to lead its operations alongside the current executive team. With Curewell’s backing, WPT plans to significantly expand its manufacturing footprint and scale its integrated services for small molecule API production in the United States.
Health Technology Insights: Tempus Partners with Whitehawk for Biomarker Oncology Research
Since its founding in 2003, WPT has built a strong reputation through its contributions to a wide range of novel drug substance programs. The company’s strengths lie in complex chemical synthesis, medicinal chemistry, scale-up processes, and GMP manufacturing. WPT delivers full-service solutions that span early drug discovery, clinical development, and commercial-scale supply, allowing it to serve as a comprehensive partner for pharmaceutical companies.
Health Technology Insights: Autonomize AI Launches Healthcare Agents Marketplace and Studio
Operating from a 54-acre headquarters in Delaware, WPT runs two adjacent facilities equipped with current good manufacturing practice (cGMP) systems. These facilities include high-potency API suites and support for registered starting materials. The company also maintains an R&D center in Suzhou, China, enhancing its global capabilities. The Delaware campus features greenfield space that has been approved for future expansion, which could include advanced biopharmaceutical manufacturing infrastructure. This positions WPT as a reliable U.S.-based partner for life science companies looking to secure local capacity and advanced capabilities.
Dr. Li expressed optimism about the partnership, noting that the collaboration with Curewell Capital aligns with WPT’s strategic vision for growth. He explained that the additional capital will allow the company to scale its operations and continue meeting the evolving needs of global biopharma partners. According to Dr. Li, WPT is focused on solving complex process development and manufacturing challenges, streamlining production, and helping bring new therapies to patients more quickly and cost-effectively.
Michael Dal Bello, a partner at Curewell Capital, said the firm is excited to work with Dr. Li and the WPT team. He praised the organization for its scientific strength and trusted reputation in the pharmaceutical industry. Dal Bello noted that the investment comes at a time when demand is rising for specialized development services and high-quality manufacturing in the U.S., and he sees WPT as well-positioned to meet that need.
Legal counsel for Wilmington PharmaTech was provided by Potter Anderson, while Kirkland & Ellis advised Curewell Capital during the transaction.
Health Technology Insights: Theravance Biopharma Launches Neurogenic Orthostatic Hypotension Education
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
